USFDA warning: Medtronic MiniMed 600 Series insulin pump system vulnerable to cyberattacks
The company said hackers, however, cannot gain access to the device through the internet.
US: The U.S. Food and Drug Administration on Tuesday warned that certain types of insulin pump systems manufactured by Medtronic were vulnerable to cyberattacks and that hackers could potentially hamper insulin delivery by accessing the device.
The agency issued a cybersecurity risk alert for the Medtronic MiniMed 600 Series insulin pump system, which has several components including an insulin pump and a blood glucose meter that communicate wirelessly.
The FDA said it was possible for an unauthorized person to gain access to a pump while it was pairing with other system components, but so far, it was not aware of any reports related to this cybersecurity vulnerability.
The insulin pumps are sold through Medtronic's diabetes segment, which brought in $2.41 billion in sales in 2021 and accounted for 8% of the company's total revenue.\
Read also: Medtronic India unveils AI Powered GI Genius Module for Colonoscopy of Colorectal Cancer
Medtronic also warned users about the risks and made recommendations including asking them to permanently turn off the "Remote Bolus" feature on the pump, not share the device's serial number with unauthorized personnel or conduct any connection linking of devices in a public place.
The company said hackers, however, cannot gain access to the device through the internet.
The FDA said it was working with Medtronic to identify, communicate and prevent adverse events related to this risk
Read also: Medtronic India launches SenSight Directional Lead System for Deep Brain Stimulation therapy
Disclaimer: This site is primarily intended for healthcare professionals. Any content/information on this website does not replace the advice of medical and/or health professionals and should not be construed as medical/diagnostic advice/endorsement/treatment or prescription. Use of this site is subject to our terms of use, privacy policy, advertisement policy. © 2024 Minerva Medical Treatment Pvt Ltd